

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
SWOG	S1400-SCCA,Adv, Biomarker Master	1	Y 1 Specimen Submission		1378	375	181	77	21	2	07/08/2014	432	223
					1378	375	181	77	21	2			
		2	Y 17 S1400G		31	31	26	5	1	0			
			2 S1400A		160	0	0	0	0	0	07/08/2014		
			3 S1400B		53	5	0	0	0	0			
			4 S1400C		88	0	0	0	0	0			
			5 S1400D		92	2	0	0	0	0			
			6 S1400E		16	0	0	0	0	0			
			7 S1400I		621	309	141	61	24	9			
					1061	347	167	66	25	9			
		3	P 10 S1400I		8	8	2	2	1	0			
			18 S1400G		8	8	5	2	2	0			
			8 S1400B		1	0	0	0	0	0	07/08/2014		
					17	16	7	4	3	0			
	S1400A-Non-Match: MEDI4736	1	N 1 MEDI4736	140	78	0	0	0	0	0	07/31/2014		
			2 Docetaxel		38	0	0	0	0	0			
					116	0	0	0	0	0			
		2	Y 3 MEDI4736	140	4	3	2	1	1	0	07/31/2014		
					4	3	2	1	1	0			
	S1400G-HRRD: Talazoparib (BMN 673)	1	Y 1 Talazoparib (BMN 673)	60	29	29	28	10	3	0	03/03/2017	432	222
					29	29	28	10	3	0			
	S1400I-Non-Match: Nivo + Ipi vs Nivo	1	Y 1 Nivolumab + Ipilimumab	350	112	60	24	11	1	0	12/29/2015	433	223
			2 Nivolumab		117	62	28	13	7	1			
					229	122	52	24	8	1			
	S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab	1	Y 1 AFATINIB + CETUXIMAB	605	70	36	25	7	3	1	05/07/2015	224	92
			2 AFATINIB		69	36	21	10	3	0			
					139	72	46	17	6	1			
	S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	1	Y 1 Trametinib + Docetaxel	53	37	37	17	0	0	0	10/05/2016	185	85
					37	37	17	0	0	0			
	8811-NSCLC, Stage III,ChemoRT+ABT-888	1	Y 5 RT+Pac+Carbo+blinded drug	132	18	18	12	6	2	1	01/24/2013	133	54

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
			6 RT+Pac+Carbo+blinded drug		14	13	7	2	2	1			
					32	31	19	8	4	2			
		2 Y 8	Pac + Carbo + blinded drug	132	17	17	14	9	3	0	01/24/2013		
					17	17	14	9	3	0			
Yes	A081105-ALCHEMIST1, EGFR mut, Erlotinib	1 E	Total Registrations		25	13	9	3	0	0	04/01/2015		248
					25	13	9	3	0	0			
	A151216-ALCHEMIST0 - screening	1 E	Total Registrations		365	198	101	63	18	2	12/16/2014	455	250
					365	198	101	63	18	2			
	C30610-SCLC, Thoracic RT	1 E	Total Registrations		52	2	2	2	0	0	05/14/2008	240	116
					52	2	2	2	0	0			
	E4512-ALCHEMIST2, ALK mut, Crizotinib	1 E	Total Registrations		5	2	2	2	1	0	02/29/2016	458	257
					5	2	2	2	1	0			
	NRGCC003-SCLC, PCI or HA-PCI	1 E	Total Registrations		4	4	3	2	1	0	10/20/2016	322	143
					4	4	3	2	1	0			
		2 E	Total Registrations		4	4	3	2	1	0	10/20/2016		
					4	4	3	2	1	0			
	R1306-NSCLC,Adv,ALK/EGFR,TargetAgents	1 E	Total Registrations		8	0	0	0	0	0	03/12/2014	162	70
					8	0	0	0	0	0			
No	A151216-ALCHEMIST0 - screening	0 E	Total Registrations		371	199	101	61	18	2	12/16/2014	455	250
					371	199	101	61	18	2			
	EA5142-ALCHEMIST3, Non-match, Nivolumab	1 E	Total Registrations		22	21	14	8	5	1	08/03/2016	454	244
					22	21	14	8	5	1			